ADMA Biologics Inc
NASDAQ:ADMA
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.7
22.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
ADMA Biologics Inc
Wall Street
Price Targets
ADMA Price Targets Summary
ADMA Biologics Inc
According to Wall Street analysts, the average 1-year price target for
ADMA
is 23.91 USD
with a low forecast of 17.4 USD and a high forecast of 27.3 USD.
ADMA Last Price Targets
ADMA Biologics Inc
The latest public price target was made on Oct 14, 2024 by
Raghuram Selvaraju
from
H.C. Wainwright
,
who expects
ADMA
stock to
drop by 15%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Raghuram Selvaraju
H.C. Wainwright
|
18
USD
Downside 15% |
1 month ago
Oct 14, 2024
|
H.C. Wainwright Reiterates Buy Rating on ADMA Biologics (ADMA)
StreetInsider
|
Anthony Petrone
Mizuho Securities
|
14
USD
Downside 34% |
5 months ago
Jun 20, 2024
|
ADMA Biologics (ADMA) PT Raised to $14 at Mizuho
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ADMA's stock price target?
Price Target
23.91
USD
According to Wall Street analysts, the average 1-year price target for
ADMA
is 23.91 USD
with a low forecast of 17.4 USD and a high forecast of 27.3 USD.
What is ADMA Biologics Inc's Revenue forecast?
Projected CAGR
27%
For the last 8 years the
compound annual growth rate for
ADMA Biologics Inc's revenue is
56%.
The projected
CAGR
for the next 3 years is
27%.
What is ADMA Biologics Inc's Operating Income forecast?
Projected CAGR
110%
The
compound annual growth rate
of ADMA Biologics Inc's operating income for the next 3 years is
110%.
You don't have any saved screeners yet
